These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 18626011)

  • 1. Microsatellites as EWS/FLI response elements in Ewing's sarcoma.
    Gangwal K; Sankar S; Hollenhorst PC; Kinsey M; Haroldsen SC; Shah AA; Boucher KM; Watkins WS; Jorde LB; Graves BJ; Lessnick SL
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10149-54. PubMed ID: 18626011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Microsatellites are EWS/FLI response elements: genomic "junk" is EWS/FLI's treasure.
    Gangwal K; Lessnick SL
    Cell Cycle; 2008 Oct; 7(20):3127-32. PubMed ID: 18927503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma.
    Kinsey M; Smith R; Iyer AK; McCabe ER; Lessnick SL
    Cancer Res; 2009 Dec; 69(23):9047-55. PubMed ID: 19920188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of two types of GGAA-microsatellites and their roles in EWS/FLI binding and gene regulation in Ewing sarcoma.
    Johnson KM; Taslim C; Saund RS; Lessnick SL
    PLoS One; 2017; 12(11):e0186275. PubMed ID: 29091716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
    Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
    Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NR0B1 is required for the oncogenic phenotype mediated by EWS/FLI in Ewing's sarcoma.
    Kinsey M; Smith R; Lessnick SL
    Mol Cancer Res; 2006 Nov; 4(11):851-9. PubMed ID: 17114343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role for the EWS domain of EWS/FLI in binding GGAA-microsatellites required for Ewing sarcoma anchorage independent growth.
    Johnson KM; Mahler NR; Saund RS; Theisen ER; Taslim C; Callender NW; Crow JC; Miller KR; Lessnick SL
    Proc Natl Acad Sci U S A; 2017 Sep; 114(37):9870-9875. PubMed ID: 28847958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emergent Properties of EWS/FLI Regulation via GGAA Microsatellites in Ewing's Sarcoma.
    Gangwal K; Close D; Enriquez CA; Hill CP; Lessnick SL
    Genes Cancer; 2010 Feb; 1(2):177-187. PubMed ID: 20827386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and biochemical function of polymorphic NR0B1 GGAA-microsatellites in Ewing sarcoma: a report from the Children's Oncology Group.
    Monument MJ; Johnson KM; McIlvaine E; Abegglen L; Watkins WS; Jorde LB; Womer RB; Beeler N; Monovich L; Lawlor ER; Bridge JA; Schiffman JD; Krailo MD; Randall RL; Lessnick SL
    PLoS One; 2014; 9(8):e104378. PubMed ID: 25093581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promiscuous partnerships in Ewing's sarcoma.
    Sankar S; Lessnick SL
    Cancer Genet; 2011 Jul; 204(7):351-65. PubMed ID: 21872822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma.
    Owen LA; Kowalewski AA; Lessnick SL
    PLoS One; 2008 Apr; 3(4):e1965. PubMed ID: 18414662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma.
    Smith R; Owen LA; Trem DJ; Wong JS; Whangbo JS; Golub TR; Lessnick SL
    Cancer Cell; 2006 May; 9(5):405-16. PubMed ID: 16697960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
    Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
    Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The oncogenic EWS-FLI1 protein binds in vivo GGAA microsatellite sequences with potential transcriptional activation function.
    Guillon N; Tirode F; Boeva V; Zynovyev A; Barillot E; Delattre O
    PLoS One; 2009; 4(3):e4932. PubMed ID: 19305498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature.
    Hancock JD; Lessnick SL
    Cell Cycle; 2008 Jan; 7(2):250-6. PubMed ID: 18256529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of target genes in their native cellular context: an analysis of EWS/FLI in Ewing's sarcoma.
    Owen LA; Lessnick SL
    Cell Cycle; 2006 Sep; 5(18):2049-53. PubMed ID: 16969112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3.
    Prieur A; Tirode F; Cohen P; Delattre O
    Mol Cell Biol; 2004 Aug; 24(16):7275-83. PubMed ID: 15282325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A zebrafish transgenic model of Ewing's sarcoma reveals conserved mediators of EWS-FLI1 tumorigenesis.
    Leacock SW; Basse AN; Chandler GL; Kirk AM; Rakheja D; Amatruda JF
    Dis Model Mech; 2012 Jan; 5(1):95-106. PubMed ID: 21979944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of EWS-ETS fusions in NIH3T3 cells reveals significant differences to Ewing's sarcoma.
    Braunreiter CL; Hancock JD; Coffin CM; Boucher KM; Lessnick SL
    Cell Cycle; 2006 Dec; 5(23):2753-9. PubMed ID: 17172842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor-specific retargeting of an oncogenic transcription factor chimera results in dysregulation of chromatin and transcription.
    Patel M; Simon JM; Iglesia MD; Wu SB; McFadden AW; Lieb JD; Davis IJ
    Genome Res; 2012 Feb; 22(2):259-70. PubMed ID: 22086061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.